All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

toripalimab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
primate origin	5757	1924598-82-2

Description:

Molecule

Description

Molfile Synonyms: toripalimab toripalimab-tpzi loqtorzi JS001 TAB001

Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Toripalimab-tpzi is a humanized IgG4 monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
Oct. 27, 2023	FDA	COHERUS BIOSCIENCES INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myelosuppression	104.12	82.47	22	110	53569	90574746

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myelosuppression	91.56	42.77	26	288	40435	42580586

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myelosuppression	167.00	56.13	50	749	94290	110494210
Hypoproteinaemia	90.93	56.13	18	781	5927	110582573
Hypothyroidism	60.93	56.13	22	777	72877	110515623

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01FF13	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
MeSH PA	D000074322	Antineoplastic Agents, Immunological
MeSH PA	D000082082	Immune Checkpoint Inhibitors
MeSH PA	D000970	Antineoplastic Agents
FDA MoA	N0000191259	Programmed Death Receptor-1-directed Antibody Interactions
FDA EPC	N0000191260	Programmed Death Receptor-1 Blocking Antibody
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:50249	anticoagulant

Related Drugs by ATC class:

L01FF PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors 11 drugs

atezolizumabavelumabcemiplimabdostarlimabdurvalumabnivolumabpembrolizumabretifanlimabserplulimabsugemalimabtislelizumab

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC)	indication	449248000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Programmed cell death protein 1	Membrane receptor	Q15116	PDCD1_HUMAN	BINDING AGENT	Kd	9.52		DRUG LABEL	DRUG LABEL

External reference:

ID	Source
CHEMBL4297843	ChEMBL_ID
C000656314	MESH_SUPPLEMENTAL_RECORD_UI
12989	IUPHAR_LIGAND_ID
DB15043	DRUGBANK_ID
4042813	VANDF
4042814	VANDF
C4763386	UMLSCUI
CHEBI:757285	CHEBI
10820	INN_ID
372988	MMSL
42134	MMSL
d10129	MMSL
019589	NDDF
8JXN261VVA	UNII
2669406	RXNORM
933451391000036109	SNOMEDCT_US
D12202	KEGG_DRUG

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
LOQTORZI	HUMAN PRESCRIPTION DRUG LABEL	1	70114-340	INJECTION	240 mg	INTRAVENOUS	BLA	29 sections